BROOMFIELD, Colo., March 14, 2016 /PRNewswire/ -- Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer's disease, today announced that Dr. Charles Stacey, President and CEO, will present at the 13th Annual BIO Asia International Conference at 2 p.m. JST on March 16 in Tokyo.
Additionally, Dr. Stacey will participate in the panel discussion called "Conducting Global Clinical Trials: Critical Success Factors to Accelerate Approvals" on the same day. Leading organizations will describe how they are designing innovative, global clinical trials earlier in drug development to satisfy multiple regulators concurrently and to reduce the total cost of drug development. New frameworks are also being proposed to harmonize regulatory requirements across regions long-term.
Japan and other Asian countries represent important territories for Accera, both in terms of its global Phase 3 program to evaluate its lead product, AC-1204 in mild to moderate Alzheimer's patients, and in the global commercial potential of the product. The prevalence of Alzheimer's in Japan and many Asian countries is expected to increase in parallel to, or even exceed, the prevalence of the disease in Western countries. Interestingly, studies have shown that the percentage of Alzheimer's patients that are APOE4 non-carriers is greater in the Asian population than in the Western population. This is particularly important for Accera as the greatest benefit of AC-1204 is observed in APOE4 non-carrier patients, and its Phase 3 clinical program is focused on demonstrating efficacy in this particular segment of the Alzheimer's population.
Accera has strong ties to Asia through its long-term investor POSCO Capital, based in Seoul, South Korea. Accera looks to use the conference to establish and develop new relationships with companies and investors in the region. The BIO Asia International Conference brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies and investors interested in research collaborations, licensing partnerships and investment with companies in the U.S. and EU.
Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colo., developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Todd Davenport, Ph.D.
(858) 717-2310 Mobile
SOURCE Accera, Inc.